Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
Ellen Weisberg, Atsushi Nonami, Zaoping Chen, et al.
Leukemia (2014) Vol. 29, Iss. 1, pp. 27-37
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Cell cycle proteins as promising targets in cancer therapy
Tobias Otto, Piotr Siciński
Nature reviews. Cancer (2017) Vol. 17, Iss. 2, pp. 93-115
Open Access | Times Cited: 1668
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
Jennifer O’Neil, Yair Benita, Igor Feldman, et al.
Molecular Cancer Therapeutics (2016) Vol. 15, Iss. 6, pp. 1155-1162
Open Access | Times Cited: 306
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
Khanh Do, Deborah Wilsker, Jiuping Ji, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 30, pp. 3409-3415
Open Access | Times Cited: 296
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 36, pp. 4371-4380
Open Access | Times Cited: 236
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Andrea Ghelli Luserna di Rorà, Claudio Cerchione, Giovanni Martinelli, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 221
DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
Laura Carrassa, Giovanna Damia
Cancer Treatment Reviews (2017) Vol. 60, pp. 139-151
Closed Access | Times Cited: 155
Targeting the replication stress response in cancer
Josep V. Forment, Mark J. O’Connor
Pharmacology & Therapeutics (2018) Vol. 188, pp. 155-167
Closed Access | Times Cited: 143
Targeting cell cycle regulators in hematologic malignancies
Eiman Aleem, R.J. Arceci
Frontiers in Cell and Developmental Biology (2015) Vol. 3
Open Access | Times Cited: 115
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer
Triparna Sen, Pan Tong, Lixia Diao, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 20, pp. 6239-6253
Open Access | Times Cited: 115
Beyond BRAF: where next for melanoma therapy?
Inna V. Fedorenko, Geoffrey T. Gibney, Vernon K. Sondak, et al.
British Journal of Cancer (2014) Vol. 112, Iss. 2, pp. 217-226
Open Access | Times Cited: 103
Directing the use of DDR kinase inhibitors in cancer treatment
Inger Brandsma, Emmy D.G. Fleuren, Chris T. Williamson, et al.
Expert Opinion on Investigational Drugs (2017) Vol. 26, Iss. 12, pp. 1341-1355
Open Access | Times Cited: 93
Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies
Sajjad Vakili‐Samiani, Abduladheem Turki Jalil, Walid Kamal Abdelbasset, et al.
DNA repair (2021) Vol. 107, pp. 103203-103203
Closed Access | Times Cited: 63
An update of predictive biomarkers related to WEE1 inhibition in cancer therapy
Zizhuo Wang, Wenting Li, Fuxia Li, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 1
Open Access | Times Cited: 12
Novel pyrimidine-2,4-dione–1,2,3-triazole and furo[2,3-d]pyrimidine-2-one–1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation
Tomislav Gregorić, Mirela Sedić, Petra Grbčić, et al.
European Journal of Medicinal Chemistry (2016) Vol. 125, pp. 1247-1267
Closed Access | Times Cited: 85
Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia
Oliver M. Dovey, Jonathan Cooper, Annalisa Mupo, et al.
Blood (2017) Vol. 130, Iss. 17, pp. 1911-1922
Open Access | Times Cited: 73
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
Liang Zhou, Yuesheng Zhang, Shucheng Chen, et al.
Leukemia (2014) Vol. 29, Iss. 4, pp. 807-818
Open Access | Times Cited: 71
Current Molecular Markers of Melanoma and Treatment Targets
Kevin Yang, Allen S. W. Oak, Radomir M. Slominski, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 10, pp. 3535-3535
Open Access | Times Cited: 69
Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology
Cédric Leroux, Georgia Konstantinidou
Cancers (2021) Vol. 13, Iss. 4, pp. 799-799
Open Access | Times Cited: 47
Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date
Amélie Boespflug, Julie Caramel, Stéphane Dalle, et al.
Therapeutic Advances in Medical Oncology (2017) Vol. 9, Iss. 7, pp. 481-492
Open Access | Times Cited: 50
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies
Ellen Weisberg, Chengcheng Meng, Abigail E. Case, et al.
British Journal of Haematology (2019) Vol. 187, Iss. 4, pp. 488-501
Open Access | Times Cited: 44
KRAS: A Promising Therapeutic Target for Cancer Treatment
Hai-zhou Wu, Jiaqi Xiao, Songshu Xiao, et al.
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 23, pp. 2081-2097
Closed Access | Times Cited: 37
Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells
Elsa N. Garza-Treviño, Adriana G. Quiroz-Reyes, Paulina Delgado‐González, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7791-7791
Open Access | Times Cited: 4
Integrated bioinformatics analysis to develop diagnostic models for malignant transformation of chronic proliferative diseases
Hua Liu, Sheng Lin, Peng Chen, et al.
Blood Science (2025) Vol. 7, Iss. 2, pp. e00226-e00226
Open Access
AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair
James B. Ford, Dmitry Baturin, Tamara M. Burleson, et al.
Oncotarget (2015) Vol. 6, Iss. 29, pp. 28001-28010
Open Access | Times Cited: 38
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
Bo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Oncotarget (2017) Vol. 8, Iss. 40, pp. 67526-67537
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top